Working… Menu

Long-term Safety Follow-up Study in the Prevention of Bronchiolitis Obliterans Syndrome (BOS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01439958
Recruitment Status : Terminated (Core study 12011.201 was terminated.)
First Posted : September 23, 2011
Last Update Posted : April 14, 2015
Information provided by (Responsible Party):
Pari Pharma GmbH

Brief Summary:
The purpose of this study is to evaluate long-term safety of L-CsA in prevention of bronchiolitis obliterans syndrome (BOS) following lung transplantation (LTx) in patients previously enrolled in phase II/III L-CsA clinical trial 12011.201.

Condition or disease Intervention/treatment Phase
Bronchiolitis Obliterans Drug: Inhalation Phase 3

Detailed Description:

This is an uncontrolled extension study open only to patients who completed the Phase II/III core study 12011.201 and volunteered to continue or to cross-over to L-CsA inhalation therapy.

Determination of long-term safety and efficacy outcome over a maximum of three years will be assessed.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Long-term Safety Follow-up Study of L-CsA Therapy for Patients Who Participated in Study 12011.201 and Volunteered to Continue or to Cross-over to L-CsA Inhalation Therapy
Study Start Date : February 2012
Actual Primary Completion Date : July 2013
Actual Study Completion Date : December 2014

Arm Intervention/treatment
Experimental: L-CsA
Twice daily inhalation of L-CsA
Drug: Inhalation
Twice daily inhalation for a maximum of three years.
Other Name: aerosolized liposomal CsA

Primary Outcome Measures :
  1. Long-term safety of L-CsA in prevention of bronchiolitis obliterans syndrome (BOS) [ Time Frame: 3 years ]
    Safety will be assesses by the numbers of treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) and overall rate of mortality.

Secondary Outcome Measures :
  1. Long-term efficacy outcome over a maximum of three years of patients previously enrolled in phase II/III L-CsA clinical trial 12011.201 [ Time Frame: 3 years ]

    Efficacy will be assessed mainly for the following efficacy endpoints:

    • BOS-free survival
    • Incidence of BOS
    • Pulmonary function

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patient has completed the L-CsA clinical trial 12011.201
  2. Patient is capable of understanding the purpose and risks of the follow-up study, has been fully informed and has given written informed consent to participate in the study
  3. Female patients of child bearing potential must test negative on standard urine pregnancy test prior to continuation and must agree to practice effective birth control during the study
  4. Estimated life expectancy > 6 months
  5. Capable of self-administration of medications
  6. Patient has stable creatinine levels

Exclusion Criteria:

  1. Patients with ongoing irreversible L-CsA related serious adverse events
  2. Patients with known hypersensitivity for ciclosporin A
  3. Patient intends to participate in another IMP clinical trial other than listed in the inclusion criteria
  4. Patient receives mechanical ventilation
  5. Patients underwent pulmonary re-transplantation
  6. Patient is a pregnant or breast-feeding woman
  7. Patient is unlikely to comply with visits, inhalation procedures or spirometric measurements scheduled in the protocol
  8. Patient receives any systemic or topical Rosuvastatin
  9. Patient has been previously enrolled in this study
  10. Patient with malignancy diagnosed during study 12011.201 (with the exception of skin cancer)
  11. Documented respiratory infections unless on appropriate antimicrobial therapy with evidence of clinical response
  12. Patient is not eligible to continue IMP inhalation according to the Investigator's discretion

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01439958

Layout table for location information
PARI Pharma GmbH
Graefelfing, Germany, 82166
Sponsors and Collaborators
Pari Pharma GmbH
Layout table for investigator information
Principal Investigator: Claus Neurohr, MD Ludwig-Maximilians - University of Munich
Layout table for additonal information
Responsible Party: Pari Pharma GmbH Identifier: NCT01439958    
Other Study ID Numbers: 12011.203
2011-004304-38 ( EudraCT Number )
First Posted: September 23, 2011    Key Record Dates
Last Update Posted: April 14, 2015
Last Verified: April 2015
Keywords provided by Pari Pharma GmbH:
Lung Transplantation
Additional relevant MeSH terms:
Layout table for MeSH terms
Bronchiolitis Obliterans
Respiratory Tract Infections
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases